Celgene pops after top proxy advisors recommend Bristol-Myers investors approve buyout

Top proxy advisors Institutional Shareholder Services and Glass Lewis on Friday recommended Bristol-Myers Squibb shareholders vote in favor of its bid to buy peer biotechnology company Celgene, according to CNBC’s David Faber.

The recommendation from ISS and Glass Lewis comes just weeks before Bristol-Myers investors will vote on whether to approve the company’s $74 billion bid for Summit, New Jersey-based Celgene.

“The transaction also significantly enhances BMY’s pipeline, raising the number of late-stage drugs from one to six,” ISS said, according to a Bristol-Myers press release Friday. “Both companies’ current products and their pipelines are focused on drugs that fight cancer and blood disorders. As such, the merger appears logical strategically, and likely to generate more synergies than one involving disparate pharmacological areas of focus.”

Though recommendations from proxy advisors like ISS do not dictate how investors vote, large passive fund managers like Vanguard and BlackRock often weigh their advice when deciding how to vote their shares. Celgene shares rose more than 7 percent in early trading, while Bristol-Myers dipped 0.2 percent in choppy trading.

“In particular, the merger represents an attractive, risk-adjusted opportunity to enhance Bristol- Myers’ product portfolio by leveraging Celgene’s current ‘Big Five’ late-stage, near-term product launches,” Glass Lewis said, according to the same Bristol press release.

However, not everyone is happy with the big-ticket biotech deal.

Investment firm Wellington Management, one of Bristol-Myers largest investors, said last month that it is opposed to the tie-up.

In a rare public comment, Wellington said it “does not believe that the Celgene transaction is an attractive path towards” a business that “secures differentiated science and broadens the future revenue base.”

Shortly thereafter, activist investor Starboard Value added that it will leverage its smaller stake in Bristol-Myers to oppose the the deal at a shareholder meeting on April 12. Starboard believes that the deal is not the best path forward for Bristol because Celgene will face headwinds once the patent for its cancer treatment, Revlimid, expires.

“Bristol-Myers is deeply undervalued and the recent announcement of the Company’s proposed acquisition of Celgene Corporation is poorly conceived and ill-advised,” Starboard CEO Jeffrey Smith wrote in a letter. “There is a better path forward for Bristol-Myers, either as a more profitable standalone company with a more focused, lower-risk strategy, or in a potential sale of the whole Company.”

A spokesperson for Wellington Management declined to comment for this story. Starboard Value did not respond to CNBC’s request for comment.

Top Oil Stocks To Invest In 2019

If you had to pick the Trump appointee who had the best 2017, a good choice would be Mike Pompeo, director of the CIA. In a year when a record number of administration officials left and a handful of others came under fire from President Trump, Pompeo is the rare team member whose fortunes have risen. He’s a key defender of the president’s policies, from Iran to China, and has shown a fierce loyalty, including a proclivity to indulge some of Trump’s views on controversial issues such as Russian meddling in the 2016 election. While that may have improved the standing of an agency Trump attacked repeatedly during his presidential campaign and the transition, it’s raised concerns about Pompeo’s commitment to keep the CIA free of politics.

As much as anyone in the administration, Pompeo has mastered the art of communicating with this president. He’s one of the first people in the Oval Office each morning when he shows up to deliver Trump the daily intelligence briefing. By most accounts, this is one of the highlights of the president’s day. Not only does Trump get details of the country’s most secretive operations, he gets them in bite-sized, boiled-down charts and graphics designed to maximize the attention of a famously fickle president.

Top Oil Stocks To Invest In 2019: Range Resources Corporation(RRC)

Advisors’ Opinion:

  • [By Tyler Crowe, Matthew DiLallo, and Reuben Gregg Brewer]

    So we asked three of our investing contributors to each highlight a company they think has a compelling investment case right now in the oil and gas industry. Here’s why they selected Devon Energy (NYSE:DVN), Range Resources (NYSE:RRC), and ExxonMobil (NYSE:XOM).

  • [By Joseph Griffin]

    Range Resources Corp. (NYSE:RRC) – Equities research analysts at Seaport Global Securities raised their Q4 2018 earnings per share (EPS) estimates for shares of Range Resources in a note issued to investors on Wednesday, May 23rd. Seaport Global Securities analyst M. Kelly now anticipates that the oil and gas exploration company will post earnings per share of $0.12 for the quarter, up from their previous forecast of $0.11. Seaport Global Securities has a “Neutral” rating on the stock. Seaport Global Securities also issued estimates for Range Resources’ Q1 2019 earnings at $0.36 EPS, Q3 2019 earnings at $0.18 EPS, Q4 2019 earnings at $0.26 EPS and FY2019 earnings at $0.98 EPS.

  • [By Paul Ausick]

    Range Resources Corp. (NYSE: RRC) fell about 3.6% Monday to post a new 52-week low of $14.77 after closing at $15.30 on Friday. The 52-week high is $35.64. Volume of about 9.4 million was about 20% higher than the daily average of around 7.7 million shares traded. The company had no specific news.

  • [By Ethan Ryder]

    OppenheimerFunds Inc. lowered its holdings in Range Resources Corp. (NYSE:RRC) by 68.2% in the first quarter, HoldingsChannel.com reports. The fund owned 30,532 shares of the oil and gas exploration company’s stock after selling 65,576 shares during the quarter. OppenheimerFunds Inc.’s holdings in Range Resources were worth $444,000 at the end of the most recent reporting period.

Top Oil Stocks To Invest In 2019: Transocean Inc.(RIG)

Advisors’ Opinion:

  • [By Shane Hupp]

    Transocean LTD (NYSE:RIG)’s share price shot up 1.5% on Thursday . The stock traded as high as $13.60 and last traded at $13.39. 771,349 shares were traded during trading, a decline of 94% from the average session volume of 13,165,396 shares. The stock had previously closed at $13.19.

  • [By Joseph Griffin]

    An issue of Transocean LTD (NYSE:RIG) debt rose 2.5% as a percentage of its face value during trading on Thursday. The debt issue has a 6.8% coupon and is set to mature on March 15, 2038. The debt is now trading at $85.45. Price moves in a company’s debt in credit markets often predict parallel moves in its share price.

  • [By Jason Hall, Tyler Crowe, and John Bromels]

    According to three Motley Fool contributors, there are still ample opportunities to profit in the oil and gas segment as some left-behind subsectors start to catch up to the higher price trend. Three in particular that are well-positioned going forward are Transocean LTD (NYSE:RIG), National-Oilwell Varco, Inc. (NYSE:NOV), and Devon Energy Corp (NYSE:DVN).  

  • [By Jason Hall and Tyler Crowe]

    In this week’s episode of Industry Focus: Energy, host Nick Sciple, together with Jason Hall and Tyler Crowe, explain how offshore companies work, where the industry is today, and what investors should watch with these companies. Tune in to learn what sets Transocean (NYSE:RIG), Diamond Offshore (NYSE:DO), Seadrill (NYSE:SDRL), and Ensco (NYSE:ESV) apart from each other, what kind of risk/reward profile each company has to offer, some critical points and trends investors need to know before diving into offshore, and much more.

  • [By Spencer Israel]

    Oil companies were popular sells for the month, including ConocoPhillips (NYSE: COP), BP p.l.c. (NYSE: BP), and Transocean Ltd. (NYSE: RIG) all net sold. Investors also net sold Alcoa Corp. (NYSE: AA), Starbucks Corporation (NYSE: CMG). and Facebook Inc. (NASDAQ: FB) in the midst of CEO Mark Zuckerberg's testimony before Congress. 

  • [By Matthew DiLallo, Jason Hall, and Tyler Crowe]

    The good news is spending is starting to bounce back in some segments, including offshore. Transocean (NYSE:RIG) recently pointed out that offshore investments in the first half of 2018 actually exceeded total 2016 offshore spending, and full-year 2018 spending is expected to be about 50% higher than last year. But unlike shale development, which can lead to new production in weeks, it’s going to take years for new offshore spending to bear results. 

Top Oil Stocks To Invest In 2019: Halliburton Company(HAL)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on Halliburton (HAL)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By ]

    Selected examples: (AAL) , (CL) , (DRI) , (HAL) , (LUV) , (MCD) , (MMM) , (SBUX) . Darden and 3M are holdings in Jim Cramer’s Action Alerts PLUS.

    What Trade War?

    Notes Goldman: “Firms expressed optimism that trade conflict would be resolved. Commentary emphasized the support for a free trade environment. Company management did not expect the disputes would escalate and affect global economic growth.”

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on Halliburton (HAL)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Stephan Byrd]

    Smith Shellnut Wilson LLC ADV purchased a new position in shares of Halliburton (NYSE:HAL) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 12,059 shares of the oilfield services company’s stock, valued at approximately $489,000.

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on Halliburton (HAL)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Taylor Muckerman]

    In this week’s episode of Industry Focus: Energy, host Sarah Priestley and analyst Taylor Muckerman go through a grab bag of questions from listeners. They explain the issues surrounding Permian Basin production, why investors might want to check out midstream company Enterprise Products Partners (NYSE:EPD), a few important things to know about oil services companies Halliburton (NYSE:HAL) and Schlumberger (NYSE:SLB), and what might become of the beleaguered offshore industry.

Top Oil Stocks To Invest In 2019: ConocoPhillips(COP)

Advisors’ Opinion:

  • [By Matthew DiLallo]

    U.S. oil giant ConocoPhillips (NYSE:COP) used $50 oil as a rough baseline for its 2019 capital plans as well. ConocoPhillips currently expects to invest $6.1 billion on capital projects this year — enough money to grow production per share by 8% — which it can fund on the cash flows produced at $40 oil. Add in a dividend that the company increased twice last year to a $3 billion repurchase program and ConocoPhillips is on track to return 50% of the cash it produces at $50 oil to investors this year, though some of that money will come from its cash-rich balance sheet. However, with oil in the mid-$50s, ConocoPhillips is on track to produce more cash than expected this year, which could lead it to buy back even more stock than planned as it works to whittle down a cash balance that stood at $6.4 billion at the end of 2018.

  • [By Zacks]

    Moreover, BP opened 100 retail sites in the country in 2017 and plans to open 1,400 more by 2021. The largest publicly traded oil company, ExxonMobil Corporation (NYSE: XOM) opened its gas stations in Mexico in December, while one of the world's biggest independent oil producers – ConocoPhillips (NYSE: COP) – showed interest in Mexico, post-reform.

  • [By Alexander Bird]

    From 2016 to 2017, Exxon Mobil Corp. (NYSE: XOM) saw a 16% boost in profits, while Chevron Corp. (NYSE: CVX) saw a 30% boost. Texas-based ConocoPhillips Corp. (NYSE: COP) saw a strong 37.5% boost.

  • [By Matthew DiLallo]

    However, the most disappointing news was that Noble Energy “plan[s] to reallocate some near-term investment to our other U.S. onshore basins,” according to CEO David Stover, due to pipeline constraints in the Permian Basin. In doing so, Noble Energy joined ConocoPhillips (NYSE:COP) in publicly announcing plans to shift spending from the fast-growing Permian to another region until new pipelines come online toward the end of next year. While ConocoPhillips is reallocating its activity to the Eagle Ford, Noble will shift to the DJ Basin.

Top buy and sell ideas by Ashwani Gujral, Sudarshan Sukhani, Mitessh Thakkar for short term

The market paused its eight days winning streak on March 22 as benchmark indices closed lower with market breadth in favour of declines. The 30-share BSE Sensex fell 222.14 points at 38,164.61, and the Nifty was down 64.10 points at 11,456.90.

According to the Pivot charts, the key support level is placed at 11,403.33, followed by 11,349.77. If the index starts moving upward, key resistance levels to watch out are 11,541.63 and 11,626.37.

The Nifty Bank index closed at 29,582.50, down 249.7 points on March 22. The important Pivot level, which will act as crucial support for the index, is placed at 29,391.43, followed by 29,200.37. On the upside, key resistance levels are placed at 29,890.83, followed by 30,199.17.

In an interview to CNBC-TV18, top market experts recommend which stocks to bet on for good returns:

related news Podcast | Stock picks of the day: Why you should buy Jubilant Food, Sundram Fasteners ‘Expect rupee to remain strong next week; bearish on the IT sector’ Aarti Drugs buyback: Here’s what investors should do

Ashwani Gujral of ashwanigujral.com

Buy L&T Finance Holdings with a stop loss of Rs 142, target of Rs 154

Buy IndusInd Bank with a stop loss of Rs 1680, target of Rs 1740

Buy SRF with a stop loss of Rs 2440, target of Rs 2500

Buy Vedanta with a stop loss of Rs 169, target of Rs 178

Buy Bata India with a stop loss of Rs 1345, target of Rs 1390

Sudarshan Sukhani of s2analytics.com

Buy Infosys with stop loss at Rs 734 and target of Rs 760

Buy Manappuram Finance with stop loss at Rs 117 and target of Rs 126

Buy Bata India with stop loss at Rs 1346 and target of Rs 1380

Sell Apollo Tyres with stop loss at Rs 219 and target of Rs 211

Sell Tata Communications with stop loss at Rs 605 and target of Rs 590

Mitessh Thakkar of mitesshthakkar.com

Sell Glenmark Pharma with a stop loss of Rs 652 and target of Rs 630

Buy Jubilant Foodworks around Rs 1425 with stop loss of Rs 1404 and target of Rs 1465

Buy SRF with a stop loss of Rs 2420 and target of Rs 2525

Sell Amara Raja Batteries with a stop loss of Rs 728 and target of Rs 690

Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com/CNBC-TV18 are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.​ First Published on Mar 25, 2019 08:28 am

5 Cheap Dividend Stocks to Buy Now

U.S. equities are skidding sideways on Wednesday as traders worry about the volatility being seen in the bond market, with long-term Treasury yields on the slide once more. This is a strong recession signal, raising fears that the Federal Reserve did permanent damage with its rate hike campaign.

With the S&P 500 still hanging around the 2,800 level, as the Dow Jones Industrial Average remains near the 26,000 level, investors are understandably getting impatient. What a perfect time to reconsider the benefits of dividend stocks, which literally pay you to wait for the market to resume its upward march.

I screened for cheap dividend stocks that are showing some upward movement, trading above their 50-day moving average, with a 3% or higher dividend yield, positive earnings growth, and a reasonable price-to-earnings and price-to-sales valuation.

Here are five to dividend stocks watch:

Compare Brokers

Ford (F)
Click to Enlarge Source: Shutterstock

Ford (NYSE:F) shares look ready to break up and out of a consolidation going back to October as F inches closer to its 200-day moving average. Ford stock carries a 6.9% dividend yield and trades at a price-to-sales multiple of just 0.2. The company is in the midst of changing its product lineup to focus on electrified vehicles, SUVs and trucks including an upcoming Mustang-inspired electric SUV.

The company will next report results on April 24 after the close. Analysts are looking for earnings of 26 cents per share on revenues of $36.53 billion. When the company last reported on Jan. 23, earnings of 30 cents per share matched expectations on a 0.5% rise in revenues.

Compare Brokers

Principal Financial Group (PFG)
Click to Enlarge Source: Shutterstock

Shares of Principal Financial Group (NASDAQ:PFG), an asset management firm, are in the midst of a consolidation range near its 200-day moving average. Watch for a rise off of its 50-day moving average to return shares to levels not seen since October for a 20% move from here. The stock provides a 4.3% dividend yield and trades at a price-to-sales ratio of just 1.

The company will next report results on April 30 after the close. Analysts are looking for earnings of $1.25 per share on revenues of $3.68 billion. When the company last reported on Jan. 29, earnings of $1.11 missed estimates by 18 cents on revenues of $3.5 billion.

Compare Brokers

The Gap (GPS)
Click to Enlarge Source: Shutterstock

Shares of Gap (NYSE:GPS) have been stabilizing and showing signs of life since management announced it would spin off its popular Old Navy brand into a separate corporate entity. The stock carries a 3.7% dividend yield and trades at 0.6 price-to-sales multiple.

The company will next report results on May 30 after the close. Analysts are looking for earnings of 33 cents per share on revenues of $3.8 billion. When the company last reported on Feb. 28, earnings of 72 cents per share beat estimates by 3 cents on a 3.2% drop in revenues.

Compare Brokers

Fidelity National Financial (FNF)
Click to Enlarge Source: Shutterstock

Shares of Fidelity National Financial (NYSE:FNF) are breaking out of a three-month consolidation below its 200-day moving average, pushing back to levels not seen since October. An extension to its October high would be worth a further 10% gain from here. The stock carries a 3.3% dividend yield and trades at a 1.3 price-to-sales multiple.

The company will next report results on May 15 after the close. Analysts are looking for earnings of 40 cents per share on revenues of $1.65 billion. When the company last reported on Feb. 13, earnings of 63 cents per share missed estimates by 5 cents on a 14.3% decline in revenues.

Compare Brokers

Xerox (XRX)
Click to Enlarge Source: Shutterstock

Shares of Xerox (NYSE:XRX) are consolidating their post-December uptrend and look ready for a resumption of upward momentum as buyers contend with overhead resistance from its 2017 and 2018 highs. The company recently shrugged off of a downgrade by analysts at Standpoint Research. The stock trades at a forward price-to-earnings multiple of less than 8 and carries a 3.1% dividend yield.

The company will next report results on April 30 before the open. Analysts are looking for earnings of 85 cents per share on revenues of $2.32 billion. When the company last reported on Jan. 29, earnings of $1.14 beat estimates by 12 cents on a 7.8% decline in revenues.

As of this writing, William Roth did not hold a position in any of the aforemen

The new face of Papa John's Pizza: Shaq

Shaquille O’Neal is joining the Papa John’s board of directors and has inked a deal to be the company’s brand ambassador.

“In addition to his business acumen, Shaquille understands how to build lasting connections with consumers and energize employees,” said Papa John’s president and CEO Steve Ritchie. 

Friday’s news is the latest in a string of changes for the world’s third-largest pizza chain, which is still working to remake its image in the wake of scandal.

The company was rocked in July 2018 after news reports surfaced that founder and chairman John Schnatter used a racial slur during a media training session. 

.oembed-frame { width: 100%; height: 100%; margin: 0; border: 0; }

Tysons chicken recall: More than 69,000 pounds of chicken strips recalled because they may contain metal

Going into space: Toyota plans to develop a 6-wheeled moon rover

The news came about eight months after Schnatter’s remarks blaming poor sales on the NFL’s handling of protests during the national anthem.

Stocks plummeted and Schnatter soon disappeared from television and promotional materials, as the company attempted to distance itself from its chief pitchman.

Now, O’Neal has signed a marketing agreement with the company, which has more than 5,000 stores and 1,200 employees.

Retired Hall of Fame basketball player Shaquille O'Neal smiles as he talks to reporters during an NBA basketball news conference in Miami on Dec. 22, 2016. (Photo: Alan Diaz, AP)

“I have truly enjoyed the high-quality Papa John’s product for years and am excited to be able to help Papa John’s raise their game to new heights,” O’Neal said in a statement. “Papa John’s is building a better culture, and I want to be a part of improving the Company from the inside out.”

It’s unclear what form that marketing agreement will take, though Shaq has long been the public face of many companies. 

In addition to his lengthy NBA career spanning from 1992 until 2011, he’s taken his large personality off the court with ventures in music, film and television. 

The NBA Hall of Famer can already be seen on television as an analyst on Inside The NBA and as a spokesperson for a variety of products, including IcyHot, Carnival cruises and The General insurance.

No stranger to the restaurant industry, O’Neal is the founder and owner of Big Chicken, a fried chicken restaurant in Las Vegas, and Shaquille’s, a restaurant in Los Angeles. 

He’s also the owner of a Krispy Kreme Doughnuts franchise in Atlanta, and as part of his pizza partnership he’ll become an investor in nine Papa John’s restaurants in the Atlanta area.

“We are thrilled to partner with Shaquille and welcome him to the Papa John’s Board,” said Jeff Smith, chairman of the Papa John’s board. “Shaquille has an excellent entrepreneurial background, including as a restaurant franchise owner, and is a natural creative marketer.”

NEWSLETTERSGet the Managing Your Money newsletter delivered to your inboxWe’re sorry, but something went wrongA collection of articles to help you manage your finances like a pro.Please try again soon, or contact Customer Service at 1-800-872-0001.Delivery: FriInvalid email addressThank you! You’re almost signed up for Managing Your MoneyKeep an eye out for an email to confirm your newsletter registration.More newsletters//staticassets.gannettdigital.com/gci-static-assets/assets/global/static-web/right-arrow@2x.png“>

Smith was named chairman of the board of directors last month after company executives agreed to sell a $200 million stake to Starboard Value, a New York-based investment fund that Smith leads. 

O’Neal’s entry comes on the heels of a deal struck with Schnatter earlier this month that avoided an all-out public battle over his membership on the board. 

John Schnatter, founder of Papa John's Pizza. – Oct. 2, 2017 (Photo: Sam Upshaw Jr./The Courier Journal )

While a special committee of the company’s directors eventually forced Schnatter out as chairman, he remained on the board. He still owns 9.9 million shares, a 26 percent stake in the company. 

Per the agreement, Schnatter agreed to resign from the board of directors while retaining a say in picking his successor. 

He also agreed to drop a lawsuit pending in Delaware that challenged a provision that prevented him from “acting in concert” with other shareholders.

While company leadership has made a number of changes, including a new customer loyalty program and revised menu items, Papa John’s continues to struggle to emerge from the scandal.

Last month, the company reported a drop in North American sales of 7.3 percent for the year and 8.1 percent for the fourth quarter of 2018.

Full year net income declined from $94.7 million in 2017 to $22.8 million last year.

“This will take time,” Ritchie, the company’s CEO, told analysts last month.

The Courier Journal previously reported that re-branding and reinvention cost the company more than $51 million in special charges last year, including $15.4 million going to help ailing franchisees. 

Papa John’s predicted last month it would spend an additional $30 million to $50 million in the first half of this year.

Ritchie has said he’s confident the strategy will work in the long run, despite the short-term pain.

Reporter Grace Schneider contributed to this story. Reporter Matthew Glowicki can be reached at 502-582-4989 or mglowicki@courier-journal.com.

Top Penny Stocks To Own Right Now

Over the years, a diminishing number of employers have offered pensions to their workers. Between the early 1990s and the early 2010s, pension plan availability fell roughly by half, from about one in three workers having access to a pension 25 years ago, to only one in six more recently. If you’re fortunate enough to work for an employer that gives you a chance to get pension payments when you retire, it’s important to know what you need to do in order to make the most of them. That way, when you decide to end your career, you’ll know you’ll be getting every penny available to you to last you the rest of your life.

Although pension income is a valuable retirement benefit that can supplement your Social Security benefits and make your retirement a lot more financially secure, it also comes with some extra responsibilities. Your monthly pension payment almost always counts as taxable income, and you’ll need to make sure that you have enough taxes withheld from your pension payments to satisfy the Internal Revenue Service.

Top Penny Stocks To Own Right Now: Aerosonic Corporation(AIM)

Advisors’ Opinion:

  • [By Logan Wallace]

    Shares of Aimia Inc (TSE:AIM) have earned a consensus rating of “Hold” from the seven research firms that are currently covering the company, Marketbeat reports. Two analysts have rated the stock with a sell rating, three have issued a hold rating and one has issued a buy rating on the company. The average 1 year price target among brokers that have covered the stock in the last year is C$3.54.

  • [By Shane Hupp]

    Aimia (TSE:AIM) has earned an average rating of “Hold” from the seven research firms that are currently covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, four have assigned a hold recommendation and one has given a buy recommendation to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is C$2.67.

Top Penny Stocks To Own Right Now: UFP Technologies Inc.(UFPT)

Advisors’ Opinion:

  • [By Joseph Griffin]

    UFP Technologies (NASDAQ: UFPT) and China XD Plastics (NASDAQ:CXDC) are both small-cap industrial products companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, risk, profitability and earnings.

  • [By Ethan Ryder]

    Media coverage about UFP Technologies (NASDAQ:UFPT) has trended somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies positive and negative press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. UFP Technologies earned a daily sentiment score of 0.03 on Accern’s scale. Accern also assigned headlines about the industrial products company an impact score of 47.0533500754779 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

  • [By Logan Wallace]

    China XD Plastics (NASDAQ: CXDC) and UFP Technologies (NASDAQ:UFPT) are both small-cap basic materials companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, institutional ownership, earnings, risk and valuation.

Top Penny Stocks To Own Right Now: Safe Bulkers Inc(SB)

Advisors’ Opinion:

  • [By Rich Smith]

    Ocean-going bulk shipper Safe Bulkers (NYSE:SB) reported its fiscal Q1 2018 earnings results on Tuesday — an “earnings beat” that nudged the company’s shares up 2%. But it took until Thursday for the real good news to arrive. Today, all of the sudden, the stock jumped out of its berth and closed 12.2% higher.

  • [By Lisa Levin] Gainers
    Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares surged 144.96 percent to close at $265.61 on Thursday in reaction to an encouraging Phase 2 clinical trial update. The clinical-stage biopharmaceutical company said its liver-directed, thyroid hormone receptor called MGL-3196 showed a statistical significance in the primary endpoint of lowering liver fat at 12 weeks and also 36 weeks.
    Viking Therapeutics, Inc. (NASDAQ: VKTX) shares rose 101.01 percent to close at $9.99 on Thursday after falling 4.42 percent on Wednesday.
    Akers Biosciences, Inc. (NASDAQ: AKER) jumped 45.58 percent to close at $0.474. The developer of rapid health information technologies said Wednesday afternoon it was granted a 180-day extension from the Nasdaq Stock Market to meet the requirement of a minimum $1.00 per share closing bid price for 10 straight days.
    Kitov Pharma Ltd (NASDAQ: KTOV) gained 40.93 percent to close at $3.03 after the FDA approved Kitov's Consensi for the treatment of osteoarthritis pain and hypertension.
    China Customer Relations Centers, Inc. (NASDAQ: CCRC) rose 28.21 percent to close at $19.86.
    J.Jill, Inc. (NYSE: JILL) climbed 26.45 percent to close at $7.84 after the company posted upbeat quarterly earnings.
    Curis, Inc. (NASDAQ: CRIS) shares climbed 21.93 percent to close at $2.78 in reaction to an encouraging FDA update. The biotechnology company that focuses on therapies for the treatment of cancer said the FDA granted a Fast Track designation for fimepinostat (CUDC-907) in patients with relapsed or refractory.
    Boxlight Corporation (NASDAQ: BOXL) gained 21.23 percent to close at $7.48.
    Kirkland's, Inc. (NASDAQ: KIRK) rose 16.21 percent to close at $12.83 after reporting upbeat Q1 results.
    The Brink's Company (NYSE: BCO) jumped 16.2 percent to close at $79.25 as the company announced plans to acquire Dunbar Armored for $520 million in cash.
    Applied Optoelectronics, Inc. (NASDAQ: AAOI) rose 15.14 percent to c
  • [By Lisa Levin]

    Check out these big penny stock gainers and losers

    Losers
    Big Lots, Inc. (NYSE: BIG) shares fell 9.6 percent to $37.01 in pre-market trading after the company reported weaker-than-expected results for its first quarter and issued downbeat earnings forecast.
    Tilly's, Inc. (NYSE: TLYS) fell 5.7 percent to $12.98 in pre-market trading after rising 12.69 percent on Thursday.
    Turkcell Iletisim Hizmetleri A.S. (NYSE: TKC) fell 4.2 percent to $6.39 in pre-market trading after dropping 4.71 percent on Thursday.
    Sunlands Online Education Group (NYSE: STG) fell 4.2 percent to $9.13 in pre-market trading.
    Safe Bulkers, Inc. (NYSE: SB) fell 4.2 percent to $3.42 in pre-market trading after climbing 12.62 percent on Thursday.
    Ulta Beauty, Inc. (NASDAQ: ULTA) fell 4.1 percent to $236.80 in pre-market trading. Ulta Beauty reported upbeat results for its first quarter, but issued weak second-quarter earnings and sales guidance.
    GameStop Corp. (NYSE: GME) shares fell 3.8 percent to $12.70 in pre-market trading. GameStop reported in-line earnings for its first quarter, while sales missed estimates.
    Workday, Inc. (NASDAQ: WDAY) fell 3.2 percent to $126.85 in the pre-market trading session after the company posted Q1 results.
    Lumentum Holdings Inc. (NASDAQ: LITE) shares fell 3 percent to $57.15 in pre-market trading

  • [By Ethan Ryder]

    Safe Bulkers (NYSE:SB) was downgraded by research analysts at ValuEngine from a “hold” rating to a “sell” rating in a research note issued on Tuesday.

  • [By Ethan Ryder]

    Evermore Global Advisors LLC trimmed its holdings in shares of Safe Bulkers, Inc. (NYSE:SB) by 24.1% during the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 1,997,101 shares of the shipping company’s stock after selling 635,851 shares during the quarter. Safe Bulkers accounts for approximately 2.2% of Evermore Global Advisors LLC’s holdings, making the stock its 14th biggest holding. Evermore Global Advisors LLC’s holdings in Safe Bulkers were worth $6,790,000 at the end of the most recent quarter.

  • [By Ethan Ryder]

    Here are some of the news articles that may have impacted Accern’s rankings:

    Get Safe Bulkers alerts:

    Safe Bulkers (SB): Moving Average Crossover Alert (finance.yahoo.com) Should Investors Have Safe Bulkers, Inc. (NYSE:SB) In Their Porfolio After Profit Growth of 0.63922? (zeelandpress.com) Detailed Research: Economic Perspectives on Safe Bulkers, SITO Mobile, Castle Brands, Motorcar Parts of America … (nasdaq.com) Simple Rule To have an eye on These Stocks:- BioTime, Inc. (NYSE:BTX), Safe Bulkers, Inc. (NYSE:SB), Mettler-Toledo … (thestreetpoint.com) Safe Bulkers, Inc. (NYSE:SB): How is this stock valued? (cantoncaller.com)

    Several research firms have commented on SB. Zacks Investment Research downgraded shares of Safe Bulkers from a “hold” rating to a “strong sell” rating in a research report on Wednesday, August 1st. ValuEngine downgraded shares of Safe Bulkers from a “hold” rating to a “sell” rating in a research report on Tuesday. TheStreet raised shares of Safe Bulkers from a “d+” rating to a “c-” rating in a research report on Wednesday, June 27th. Seaport Global Securities raised shares of Safe Bulkers from a “neutral” rating to a “buy” rating and increased their target price for the stock from $3.50 to $5.00 in a research report on Tuesday, July 31st. Finally, Maxim Group reissued a “buy” rating and set a $6.00 target price on shares of Safe Bulkers in a research report on Monday, July 23rd. Three analysts have rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $3.79.

Top Penny Stocks To Own Right Now: Patni Computer Systems Limited(PTI)

Advisors’ Opinion:

  • [By Chris Lange]

    Proteostasis Therapeutics Inc. (NASDAQ: PTI) saw its shares slide early on Thursday after the company reported that it had positive data from its early stage trial in cystic fibrosis (CF). These results come from the firm’s ongoing Phase 1 dosing study of PTI-801 in CF patients on background Orkambi (lumacaftor/ivacaftor) therapy.

S&P is having its best quarter since 2009, and history points to another surge

The S&P 500 is on track for its best quarter in a decade, up roughly 12 percent. And if history is any indication, the index could be set for more gains for the rest of the year.

In nine of the 10 previous times since 1950 that the S&P returned more than 10 percent in the first quarter, it went on to post double-digit gains for the year, according to LPL Financial’s Ryan Detrick. The one exception was 1987, when the market crashed on Black Monday.

Despite the track record, S&P Global’s Erin Gibbs and Instinet’s Frank Cappelleri believe the S&P still has a number of hurdles to surpass before it can move meaningfully higher.

Gibbs points out that this quarter’s strong surge is different from prior examples: Rather than being an extension of fourth-quarter strength, this time stocks limped into the new year after sliding at the end of 2018. So the index is just recovering lost ground, she said.

“We still haven’t even recovered from the carnage that we just went through in the fourth quarter, so I think this is still really reclassified as more of a rebound rather than a continuation of an uptrend that we saw in all those other years,” Gibbs said Tuesday on CNBC’s “Trading Nation.”

“So I’m really hesitant in forecasting being up another 20 percent or 25 percent when you combine that with the high valuations as well as less than 3 percent profit growth expected for this year,” she added.

After looking at the charts, Cappelleri argues that the S&P has been stuck in a range. He doesn’t forecast new highs until the index can materially break — and hold — above the key 2,800 level, which has provided resistance in the past.

“Before we can talk about extension for the rest of the year, we need to get through 2,800 first,” he said in the segment. “By my count it’s encountered this level or this area near 2,800 now 12 times since the beginning of 2018, and I know back then it marked a key breakdown point twice in January, and again in October. … It’s in rebound form now. And so we still need to get through that point.”

Putting the S&P’s struggle to move higher in historical context, Cappelleri argues that this is the fourth failed major topping pattern since 2009. The charts exhibited similar patterns in 2010, 2011 and 2016, when the S&P broke below a key support line, before ultimately surging to new highs.

So while Cappelleri thinks that ultimately the chart’s pattern shows a rally could be ahead, he says the index won’t make new highs until it can hold that key 2,800 level.

Disclaimer

Is Snap Stock Headed for $20?

I read an article about Snap (NYSE:SNAP) CEO Evan Spiegel recently that was highly complimentary of the 28-year-old wunderkind. It got me thinking about Snap stock, which went over $10 on Mar 13 for the first time in six months, a hallelujah moment if there ever was one for Spiegel and the rest of Snap’s management team.

Snap Inc (SNAP) Stock: The Gains Will Be EphemeralSnap Inc (SNAP) Stock: The Gains Will Be EphemeralSource: Shutterstock

With Snap stock on a roll, is $20 the next logical target for Snap stock?

Yes and no. Here’s why.

Why $20 Could Be in the Cards for Snap Stock

My InvestorPlace colleague Josh Enomoto paid me a nice compliment recently. And it just happened to be related to Snap stock.

“Certainly, those who recommended speculating on SNAP stock finally have credibility. Last September, InvestorPlace’s Will Ashworth stated that SNAP stock was worth gambling on as long as it stayed under $10. As is usually the case, he was right on the money. Year-to-date, SNAP stock is up over 69%,” Enomoto wrote February 19.  

While Josh’s words are very kind, he knows all too well that the business of investment prognostication is one-third analysis and two-thirds luck. As they say, “Even a blind squirrel finds an acorn once in a while.”

In my September article, I made it abundantly clear that I wouldn’t buy Snap stock. Now that it’s doubled in price, I still wouldn’t.

The question is whether you should.

I’ve not always been a fan of Spiegel’s. In July 2017, I questioned the wisdom of Speigel and his wife, Miranda Kerr putting their wedding photos on Instagram, Facebook’s (NASDAQ:FB) website which threatens Snapchat’s very existence.

“I have to wonder about their decision to put the photos on Instagram — one of the social media apps that could put Snap out of business, ultimately sending SNAP investors scrambling to buy FB stock, if they already haven’t,” I wrote.  

However, I have to give him credit for risking it all in the short-term for an app redesign that would deliver consistent revenue and profit growth in the long-term. It’s not easy to take that kind of risk when the entire world is telling you that you’re making a huge mistake.

But innovation is what drives great companies.

Compare Brokers

That’s why I’m a huge fan of Elon Musk’s despite the fact that he’s as erratic a CEO as Donald Trump is a President. However, when I read stuff like I did earlier this week about Tesla (NASDAQ:TSLA) updating the Model 3’s software to give the car 5% more power, I bow down to the innovation master. It’s brilliant.

Referring back to the beginning where I mentioned a recent article that got me thinking about Snap stock, iHeart Radio CEO Bob Pittman, who once was a top executive at Time Warner, said something very telling about Spiegel and Snapchat.

“Anytime you do a redesign of anything, you get a backlash because you’ve changed what people already know,” Pittman said. “If you’re going to drive consumer products, you have to be willing to keep evolving it and moving it. I think Evan is probably one of the prime examples of someone who’s willing to do that.”

Now, before you get on the computer to buy Snapchat stock, it’s important to know that iHeart Radio is a Snapchat partner, so his comments have to be taken with a modicum of caution

That said, Spiegel’s got the innovation chops to get Snap to non-GAAP and then GAAP profitability. But it’s going to take some more time.

Why $20 May Not Be in the Cards for Snap Stock

The one thing I didn’t mention about my colleague, Josh Enomoto, is that he knows a thing or two about technology. That makes him a better evaluator of Snap’s prospects than myself.

Here’s what he had to say in mid-February.

“When it comes to ARPU, whom is SNAP going to target for revenue opportunities? Snapchat’s advertisement sales and engagement run a distant third to Facebook and Twitter(NYSE:TWTR), who are first and second, respectively,” Josh wrote.

“Even more problematic, media and entertainment firms run the most advertisements on Snapchat’s platform. That’s fine, but the company won’t be able to raise its ARPU by selling ads to companies in other sectors.”

Essentially, what he’s saying, is that the chances of SNAP delivering a string of earnings beats beyond its impressive Q4 surprise are very small. As Snap stock has appreciated another 15% since mid-February, any negative surprise when it reports first-quarter earnings at the end of April will most certainly send the SNAP stock price diving into single digits.  

In other words, there’s still a lot of risks associated with Snap stock, and those risks may have increased now that it’s doubled in price.

The Bottom Line on Snap Stock

I would love to say I know for sure that SNAP will go to $20. If I did, I wouldn’t be writing about its stock; I’d be making money from it.

At $5, it was easy to recommend that aggressive investors take a shot at SNAP stock. At $10, the odds of it doubling a second time in a year are low to non-existent.

However, if you have the stones to handle a lot of risks, it’s one of the more intriguing low-priced bets available in today’s market.  

It’s not one I’d take, but that doesn’t mean you shouldn’t.

At the time of this writing Will Ashworth did not hold a position in any of the aforementioned securities.

Here’s what could bring an end to the market’s IPO high, according to one expert

There’s a chance this year’s IPO boom goes bust, according to one specialist.

The tidal wave of highly anticipated initial public offerings has already begun, with Levi Strauss re-entering the public sphere last week. Still on the horizon are the IPOs of popular ride-hailing services Lyft and Uber, along with Pinterest, Airbnb and others.

But IPO specialist Kathleen Smith is wary of some of the coming offerings. Her firm, Renaissance Capital, runs an IPO-themed exchange-traded fund called the Renaissance IPO ETF that is up over 30 percent year to date.

“A very important test is going to be how the market reacts to these money-losing ones: Lyft, Uber, Pinterest,” Smith said Monday on CNBC’s “ETF Edge.” “How are they going to be priced and traded?”

Wall Street’s reaction will set the tone for this year’s tidal wave of IPOs, and whether their valuations — many of which are in the tens of billions of dollars — can hold up, in some cases against their well-documented unprofitability, said Smith, who co-founded Renaissance Capital.

“We knew that our ETF, as it performed so well this year, meant [that] the window’s opening for IPOs. We know from our studies [that] the early ones out are always the better performers for investors,” she added.

Still, Smith said that even this potential hurdle doesn’t bring 2019 close in comparison to the early-2000s dot-com bubble, when a glut of newly public internet companies drove the technology sector into disarray.

“The IPO market now, as opposed to the internet bubble, is much more institutional, so we’re expecting the price discovery to be pretty good compared to what it was in the bubble period,” Smith said. “It means that big institutions are going to control the ownership, early on, of these companies.”

And while that means smaller institutions and individual investors will have to find more strategic times to buy in, Smith stressed that Renaissance’s ETF takes some of that difficulty out of the equation.

“It’s a rolling, two-year population of the largest and most liquid IPOs [that is] rebalanced every quarter,” she said. “For very large companies, they’ll come in pretty soon after the IPO starts trading. So, large ones like Lyft, Uber, [will] all be constituents on a fast-entry basis into our index.”

“We are the first ETF to own these new companies. There are no other ETFs that are picking them up so early,” she said, adding that while the S&P 500 took two years to add Facebook’s stock to its holdings, Renaissance invested in it “within a week of its IPO.”

The Renaissance IPO ETF traded less than 1 percent higher Monday.

Disclaimer

Top 5 Biotech Stocks To Invest In Right Now

Newlan’s Truism: An “acceptable” level of unemployment means that the government economist to whom it is acceptable still has a job.

I get asked quite a bit this time of year of what my favorite growth play among large cap concerns in the biotech sector is for the year ahead. One name continues to stand out. It is a name not surprisingly that is showing up in the top large cap picks list within biotech for 2017 at such places as Merrill Lynch and RBC Capital.

Celgene (NASDAQ:CELG) should be known to just about every biotech investor. I can think of no other large cap industry player that has a clearer earnings growth trajectory over the next 3-5 years. Celgene is not going to be “home run” investment, but I expect it to continue to deliver “singles” every year with an occasional “double” in some years.

Click to enlarge

Top 5 Biotech Stocks To Invest In Right Now: Biogen Idec Inc(BIIB)

Advisors’ Opinion:

  • [By Sean Williams]

    Of course, my “bet against all Alzheimer’s drugs” thesis took a bit of a hit last week when biotech blue-chip Biogen (NASDAQ:BIIB), which is working alongside partner Eisai (NASDAQOTH:ESALY), reported positive mid-stage data on blockbuster hopeful BAN2401.

  • [By George Budwell]

    Not surprisingly, biotech titans Celgene (NASDAQ:CELG) and Biogen (NASDAQ:BIIB) are among the leaders in this ongoing biopharma revolution. So, with that theme in mind, let’s attempt to gauge which of these top biotechs is the more attractive long-term buy for investors right now.

  • [By Shannon Jones]

    In this week’s episode of Industry Focus: Healthcare, host Michael Douglass and Motley Fool contributor Shannon Jones look at what went wrong with Incyte’s Epacadostat, where the company can go from here, and what this unfortunately means for the immuno-oncology sector on the whole. Then, in more pleasant news, the hosts dive into Novartis’ (NYSE:NVS) newest acquisition of gene therapy company AveXis. Find out what this means for Novartis, why Biogen (NASDAQ:BIIB) might be getting the stink eye from their investors right about now, whether or not Novartis overpaid to tuck this company under their belt, and more.

Top 5 Biotech Stocks To Invest In Right Now: Alnylam Pharmaceuticals Inc.(ALNY)

Advisors’ Opinion:

  • [By Jim Crumly]

    As for individual stocks, shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) fell despite the announcement of its first-ever drug approval, and those of Sysco (NYSE:SYY) rose on earnings.

  • [By Sean Williams, Chuck Saletta, and Brian Feroldi]

    So, which biotech stocks should you consider buying in June? That’s a question we posed to three of our healthcare-focused investors. Interestingly enough, mid-cap biotech stocks are the clear flavor of the month. If biotech is on your radar in June, our investors suggest you consider Ionis Pharmaceuticals (NASDAQ:IONS), Spark Therapeutics (NASDAQ:ONCE), and Alnylam Pharmaceuticals (NASDAQ:ALNY).

  • [By Brian Orelli]

    Earlier this week, Dicerna released promising interim phase I data for its lead drug, DCR-PHXC, in patients with primary hyperoxaluria type 1 and type 2. The company plans to start a trial to be used to support an FDA approval in the first quarter of 2019, but that’ll put it behind Alnylam Pharmaceuticals (NASDAQ:ALNY), which is about to start a phase 3 study testing its drug, lumasiran, in patients with primary hyperoxaluria type 1. Hopefully, Dicerna can use some of its new capital to help accelerate enrollment in its trial to try to catch up to Alnylam.

  • [By Max Byerly]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, May 3rd. The biopharmaceutical company reported ($1.41) EPS for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.06. The business had revenue of $21.90 million during the quarter, compared to analysts’ expectations of $35.23 million. Alnylam Pharmaceuticals had a negative return on equity of 36.81% and a negative net margin of 565.20%. The business’s quarterly revenue was up 15.3% on a year-over-year basis. During the same quarter in the prior year, the business posted ($1.25) earnings per share. equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -6.7 earnings per share for the current fiscal year.

  • [By Keith Speights]

    Speaking of competition, Ionis should have its hands full battling rivals for Tegsedi assuming the drug wins approval. Alnylam (NASDAQ:ALNY) anticipates winning FDA approval for its hATTR drug patisiran within a few weeks. Because the FDA delayed its decision on Tegsedi, Alnylam appears to be in position to reach the market first. In addition to its first-mover advantage, patisiran appears to have an edge over Tegsedi in efficacy and safety based on clinical data for the two drugs. 

  • [By Keith Speights]

    I wrote three months ago that I viewed Alnylam Pharmaceuticals (NASDAQ:ALNY) stock as a pretty good pick — but with a couple of qualifications. First, I didn’t think that the biotech would generate returns in 2018 nearly as great as it did last year. Second, I thought that there were even better stocks to buy than Alnylam.

Top 5 Biotech Stocks To Invest In Right Now: ArQule Inc.(ARQL)

Advisors’ Opinion:

  • [By Max Byerly]

    Get a free copy of the Zacks research report on ArQule (ARQL)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Joseph Griffin]

    ValuEngine upgraded shares of ArQule (NASDAQ:ARQL) from a buy rating to a strong-buy rating in a research report released on Tuesday.

    Several other equities analysts have also issued reports on ARQL. Zacks Investment Research upgraded ArQule from a hold rating to a buy rating and set a $2.50 price objective for the company in a research report on Tuesday, March 20th. BidaskClub upgraded ArQule from a buy rating to a strong-buy rating in a research report on Saturday, March 24th. B. Riley set a $4.00 price objective on ArQule and gave the company a buy rating in a research report on Monday, March 26th. Leerink Swann upgraded ArQule from a market perform rating to an outperform rating in a research report on Thursday, April 5th. Finally, Roth Capital boosted their price objective on ArQule from $5.00 to $6.00 and gave the company a buy rating in a research report on Tuesday, April 17th. One equities research analyst has rated the stock with a sell rating, five have assigned a buy rating and two have issued a strong buy rating to the stock. The company has a consensus rating of Buy and a consensus target price of $5.35.

  • [By Maxx Chatsko]

    Shares of development-stage biopharma ArQule (NASDAQ:ARQL) rose nearly 17% today after the company announced two appointments to its management team in two newly created positions. Dr. Marc Schegerin will serve as senior vice president, corporate strategy, communication, and finance. Dr. Shirish Hirani will serve as senior vice president, program management and product planning. 

  • [By Joseph Griffin]

    ArQule (NASDAQ:ARQL)‘s stock had its “buy” rating restated by equities researchers at Needham & Company LLC in a research report issued to clients and investors on Tuesday, Marketbeat Ratings reports. They currently have a $6.00 price target on the biotechnology company’s stock, up from their prior price target of $5.00. Needham & Company LLC’s price target suggests a potential upside of 134.38% from the company’s previous close.

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on ArQule (ARQL)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 5 Biotech Stocks To Invest In Right Now: Amgen Inc.(AMGN)

Advisors’ Opinion:

  • [By Keith Speights]

    If you’re looking to invest in successful big biotechs, two of the biggest are Amgen (NASDAQ:AMGN) and Celgene (NASDAQ:CELG). Over the past 10 years, both stocks have more than tripled.  

  • [By Dan Caplinger]

    The iShares biotech ETF has a structure that’s familiar to anyone who invests regularly in exchange-traded funds. The ETF tracks an index of nearly 200 biotech and pharmaceutical stocks, with roughly 80% of assets dedicated to true biotechs and the rest split evenly between pharma and life sciences equipment and services providers. Top ETF holdings Biogen (NASDAQ:BIIB), Amgen (NASDAQ:AMGN), and Gilead Sciences (NASDAQ:GILD) make up a total of roughly 25% of the fund’s assets.

  • [By ]

    Amgen (Nasdaq: AMGN) — Amgen is a leading global biotech developer with a diverse product portfolio and promising development pipeline. The company has special expertise in cancer research and renal failure (kidney disease) treatments. Its biggest blockbuster is the anti-inflammatory drug Enbrel, used primarily for rheumatoid arthritis, which is in the top-five worldwide with annual sales of nearly $8 billion.